Stocks Health care LEXX
NASDAQ · Health careLexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. brought in $194K of revenue over the twelve months to May 31, 2026, down 68.5% from a year earlier. It posted a net loss of $7.7M. In fiscal 2025 capital spending exceeded operating cash flow by $10.5M. At May 31, 2026 it held $3.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 13, 2026.
Key facts about Lexaria Bioscience Corp.
- Net worth
- Lexaria Bioscience Corp. has a market value (market cap) of $7.7M at the latest share price, and shareholders' equity of $4.7M on its balance sheet at May 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $705.9K (+52.0% year on year), with a net loss of $11.9M. Over the 12 months to May 31, 2026: revenue $194K, net loss $7.7M.
- Cash flow
- In fiscal 2025 operations used $10.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 13, 2026 and covers the period to May 31, 2026. Open on SEC EDGAR
- Next earnings report
- Lexaria Bioscience Corp.'s next report is expected around November 27, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Lexaria Bioscience Corp. does
Lexaria Bioscience Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LEXX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $705.9K | -$11.9M | -$0.66 | -$10.5M |
| 2024 | $464.3K | -$5.8M | -$0.47 | -$5M |
| 2023 | $226.2K | -$6.7M | -$1.01 | -$5.9M |
| 2022 | $255.4K | -$7.3M | n/a | -$4.9M |
| 2021 | $722.7K | -$4M | -$0.95 | n/a |
| 2020 | $384.5K | -$4.1M | -$1.47 | -$2.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LEXX ranks in Health care
Latest SEC filings
What Lexaria Bioscience Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026
- September 9, 2026
- September 1, 2026Other event 8-K
- August 17, 2026Other event 8-K
- August 10, 2026
- July 30, 2026
- July 13, 2026
- April 13, 2026Quarterly report 10-Q · period to February 28, 2026Revenue fell 89% to $20K versus the same quarter last year; diluted EPS -$0.06 versus -$0.15.
- February 6, 2026
- January 28, 2026
Insider trades
What the people running Lexaria Bioscience Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 17, 2026 | Bunka ChristopherDirector | Gave as a gift | 100,000 | - |
Who owns LEXX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
1 insiders reported holding 273,543 shares in total, about $1.3M at the last price.
| Holder | Shares |
|---|---|
| Bunka ChristopherDirector | 273,543 |
Questions about LEXX
What does Lexaria Bioscience Corp. do?
Lexaria Bioscience Corp. is a company in the Health care sector, listed on NASDAQ as LEXX. Its shares trade on NASDAQ under the ticker LEXX.
What is Lexaria Bioscience Corp.'s net worth?
Lexaria Bioscience Corp. has a market value (market cap) of $7.7M at the latest share price, and shareholders' equity of $4.7M on its balance sheet at May 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lexaria Bioscience Corp. profitable?
No. Over the twelve months to May 31, 2026 it reported a net loss of $7.7M on revenue of $194K.
How much revenue does Lexaria Bioscience Corp. make?
Over the twelve months to May 31, 2026 Lexaria Bioscience Corp. reported revenue of $194K. That is 68.5% less than a year earlier.
When did Lexaria Bioscience Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 13, 2026. It covers the period to May 31, 2026. Its newest filing of any kind is the shelf registration to sell securities from October 2, 2026.
When is Lexaria Bioscience Corp.'s next earnings report?
Lexaria Bioscience Corp.'s next report is expected around November 27, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LEXX with
Follow LEXX
Get an email when Lexaria Bioscience Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lexaria Bioscience Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.